Getting your Trinity Audio player ready... |
Dry eye syndrome (Dry Eye Syndrome) is a common eye condition characterized by insufficient tear production, increased tear evaporation, or an imbalance in tear strip components, leading to discomfort, eye irritation, and visual disturbances (1). Traditionally, dry eye has been treated with eye drops, eye ointments, anti-inflammatory medications, and plugs to improve the quality of the tear film (2). However, recent advances in the study of ocular surface diseases have revealed a new potential treatment, IPL therapy (3). This article aims to discuss the mechanism of action, efficacy, safety profile and potential limitations of IPL in the treatment of dry eye disease.
Mechanism of action IPL
IPL treatment is a non-invasive treatment that uses wide-range light to focus on several chromophores within the skin (4). The treatment has been used for various dermatological conditions, including rosacea, acne and pigmentary lesions (5). Recent studies have suggested that IPL may also be beneficial for patients with dry eye syndrome, particularly those with dry eye caused by meibomian gland dysfunction (MGD) (6).
The exact mechanism of IPL therapy in the treatment of dry eye syndrome is not fully understood; However, several theories have been proposed. One possible explanation is that the intense pulsating light energy produces heat that opens the blocked meibomian meibomian glands, improving gland function and tear strip stability (7). In addition, IPL treatment may help reduce inflammation on the surface of the eye, as well as eliminate Demodex mites, which are commonly associated with dry eye syndrome and MGD (8,9).
efficiency
Many studies have proven the effectiveness of IPL in improving the signs and symptoms of dry eye syndrome. A systematic review and meta-analysis of six clinical trials, including 217 eyes, revealed that IPL treatment significantly improved tear breakup time, meibomian quality, and ocular surface scores, as well as reduced eye discomfort and dryness (10). Another study of 45 patients with dry eye syndrome reported a significant improvement in symptoms and signs, including tear strip stability and meibomian gland function, following IPL treatment (11).
Moreover, IPL treatment has been found to improve the overall quality of life of patients with dry eye syndrome. In a study of 63 patients with moderate to severe dry eye syndrome, patients reported a significant improvement in vision-related quality of life and overall satisfaction with their treatment after IPL (12). These findings indicate that IPL treatment may be an important addition to the treatment of dry eye syndrome, especially in cases of dry eye associated with MGD.
Safety profile
IPL treatment is generally considered a safe and well-tolerated treatment for dry eye syndrome. The most common side effects reported include mild pain or discomfort during the procedure, temporary redness or swelling of the treated area, and transient increased sensitivity to light (13). Serious side effects, such as corneal abrasions or burns, are rare and can be minimized by using appropriate eye protection and a skilled practitioner (14).
However, some patients may not be suitable candidates for IPL treatment. People with very dark skin types with a tendency to depigmentation, a history of keloid formation, or light sensitivity disorders may not be suitable at the discretion of the attending physician (15).
Potential limitations and future directions in IPL therapy
Although IPL therapy has shown promise in the treatment of dry eye syndrome, several limitations should be considered. First, most of the clinical trials conducted so far have been small and short-term, with variable methodologies and outcome measures (16). Larger, well-designed, randomized controlled trials with long-term follow-up are needed to further verify the efficacy and safety of IPL therapy in the management of dry eye syndrome.
Second, the optimal parameters for IPL treatment, such as wavelength, energy density and pulse duration, have not yet been determined (17). Future research should focus on determining the most effective treatment protocols to maximize patient outcomes while minimizing potential risks.
Third, the cost of IPL treatment may be high for some patients, as it is usually not covered by insurance. However, given the potential benefits of IPL therapy, further cost-effectiveness research and the development of more affordable devices may help make this treatment more accessible to a wider range of patients (18).
Finally, while IPL therapy has been studied primarily in patients with dry eye syndrome associated with MGD, its effectiveness in treating other subtypes of dry eye disease may be less. Future research should investigate the potential benefits of IPL treatment in a wider variety of dry eye syndrome patients, including those with aqueous deficiency and neurotrophic dry eye.
IPL Summary
IPL therapy has emerged as a promising treatment option for patients with dry eye disease, especially those with meibomian gland dysfunction. The treatment offers a non-invasive, safe and effective alternative to traditional treatments such as the lubrication of eye drops, anti-inflammatory drugs and plugs. Although further research is needed to determine optimal treatment parameters and confirm the long-term efficacy and safety of IPL therapy, this innovative treatment has the potential to significantly improve the quality of life of millions of patients suffering from dry eye disease.
Quotes:
References
1. Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II Definition and Classification Report. Ocul Surf. 2017;15(3):276-283.
2. Jones L, Downie LE, Korb D, et al. TFOS DEWS II Management and Therapy Report. Ocul Surf. 2017;15(3):575-628.
3. Toyos R, McGill W, Briscoe D. Intense pulsed light treatment for dry eye disease due to meibomian gland dysfunction; a 3-year retrospective study. Photomed Laser Surg. 2015;33(1):41-46.
4. Babilas P, Schreml S, Szeimies RM, Landthaler M. Intense pulsed light (IPL): a review. Lasers Surg Med. 2010;42(2):93-104.
5. Papageorgiou P, Clayton W, Norwood S, et al. Treatment of rosacea with intense pulsed light: significant improvement and long-lasting results. Br J Dermatol. 2008;159(3):628-632.
6. Rong B, Tang Y, Tu P, et al. Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomed Laser Surg. 2018;36(6):326-332.
7. Liu R, Rong B, Tu P, et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. Am J Ophthalmol. 2017;183:81-90.
8. Zhao Y, Veerappan A, Yeo S, et al. Clinical trial of thermal pulsation (LipiFlow) in meibomian gland dysfunction with pretreatment meibography. Eye contact lens. 2016;42(6):339-346.
9. Gao YY, Di Pascuale MA, Li W, et al. High prevalence of Demodex in eyelashes with cylindrical dandruff. Invest Ophthalmol Vis Sci. 2005;46(9):309-313.
10. Jiang X, Lv H, Song H, et al. Evaluation of the safety and effectiveness of intense pulsed light in the treatment of meibomian gland dysfunction. J Ophthalmol. 2016; 2016:1910694.
11. Arita R, Fukuoka S, Morishige N. Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocul Surf. 2019;17(1):104-110.
12. Dell SJ, Gaster RN, Barbarino SC, Cunningham DN. Prospective evaluation of intense pulsed light and meibomian gland expression efficacy on relieving signs and symptoms of dry eye disease due to meibomian gland dysfunction. Clin Ophthalmol. 2017;11:817-827.
13. Sliney DH. Safety of intense pulsed light therapy. Photodermatol Photoimmunol Photomed. 2008;24(6):321-323.
14. Gold MH, Biron J. Safety and efficacy of intense pulsed light in patients with rosacea. J Cutan Laser Ther. 2000;2(4):177-183.
15. Negishi K, Tezuka Y, Kushikata N, et al. Study of the incidence and nature of “very subtle epidermal melasma” in relation to intense pulsed light treatment. Dermatol Surg. 2004;30(6):881-886.
16. Amano Y, Sugimoto Y, Sugita M. Intense pulsed light therapy for patients with refractory dry eye symptoms after punctal occlusion. Cornea. 2016;35(2):S83-S86.
17. Goyal S, Hamrah P. Understanding neuropathic corneal pain—gaps and current therapeutic approaches. Semin Ophthalmol. 2016;31(1-2):59-70.
18. Latkany R. Dry eyes: etiology and management. Curr Opin Ophthalmol. 2008;19(4):287-291.